Prenatal and Newborn Genetic Testing Market Expected to Reach $14,727.30 Million by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Prenatal and Newborn Genetic Testing Market,"

The Prenatal and Newborn Genetic Testing Market Size was valued for $4,891.51 million in 2021 and is estimated to reach $14,727.30 million by 2031, exhibiting a CAGR of 11.5% from 2022 to 2031. 

Prenatal screening is performed during pregnancy and after to detect fetal genetic abnormalities. It also helps to detect sex of the fetus at an early stage of pregnancy. Prenatal tests are recommended to detect genetic abnormalities and congenital conditions at an early stage of pregnancy. There are various genetic tests approved by the health services such as polymerase chain reaction, fluorescence in-situ hybridization, and assays for diagnosis. There are various prenatal and newborn screening methods adopted such as non-invasive prenatal screening (NIPT), chronic villus sampling, maternity serum screening, and others.  

Prenatal and Newborn Genetic Testing Market Trends include growth in awareness about prenatal testing and rise in the adoption of technologically advanced prenatal and an increase in awareness toward the benefits of using prenatal and newborn genetic testing in the effective diagnosis of genetic abnormalities. For instance, the California Department of Public Health offers a Prenatal Screening Program to all pregnant individuals in California. This program offers cell-free DNA (cfDNA) screening and maternal serum alpha-fetoprotein (MSFP) screening.  

However, risk associated with screening test limit the adoption of genetic testing methods and devices. For example, screening tests for Down’s syndrome and Patau syndrome have chances of miscarriage. In addition, high cost of screening test and diagnostic methods further limit the market's growth.  

Moreover, rise in the number of pregnancies is the key factor expected to provide a lucrative opportunity for the Prenatal and Newborn Genetic Testing Market Growth during the forecast period. For instance, a report of the Centers for Disease Control and Prevention (CDC), published in 2020, shows a 1% increase in births from 2020, with 3,659,289 births recorded in 2021.  

On the basis of product type, the market is bifurcated into instruments and consumables. Depending on the screening the market is divided into chronic villus sampling (CVS), amniocentesis, maternal serum screening (MSS), and others. On the basis of disease, the market is fragmented into Down’s syndrome, phenylketonuria, cystic fibrosis, sickle cell disease, and others. On the basis of end users, the market is differentiated into hospitals, maternity and specialty clinics, and diagnostic centers.  

On the basis of product type, the Prenatal and Newborn Genetic Testing Industry is classified into instruments and consumables. The consumables segment has the highest Prenatal and Newborn Genetic Testing Market Share in 2021, owing to rise in the number of pregnant women and an increase in newborn screening for genetic testing. For instance, according to the article published by Healthy Moms. Strong Babies., in July 2020, about 4 million babies are screened every year in the U.S. However, diagnostic is the fastest growing segment during the forecast period, owing to rise in the adoption of prenatal and newborn testing in developing countries.  

On the basis of screening the market is segmented into non-invasive prenatal testing (NIPT), chronic villus sampling (CVS), amniocentesis, maternal serum screening (MSS), and others. non-invasive prenatal testing (NIPT) is the largest and fastest-growing segment during the forecast period owing to, a rise in awareness about prenatal testing and an increase in the number of pregnant women undergoing maternal serum screening.  

On the basis of disease, the market is classified into Down’s syndrome, phenylketonuria, cystic fibrosis, sickle cell disease, and others. The Down syndrome segment dominated the market in 2021 owing to a rise in the prevalence of Down syndrome in newborn babies. For instance, according to the Centers for Disease Control and Prevention (CDC), about 1 in every 700 babies born will have Down’s syndrome. On the other hand, phenylketonuria is the fastest-growing segment during the forecast period owing to the rise in the number of babies born with phenylketonuria.  

On the basis of end user, the market is classified into hospitals, maternity and specialty clinics, and diagnostic centers. The hospital segment dominated the market in 2021 owing to, an increase in the number of hospitals and rise in the number of patients undergoing screening from hospital facilities. However, the maternity and specialty clinics segment is the fastest-growing segment during the forecast period. This is attributed to the availability of advanced screening equipment and healthcare staff.  

On the basis of region, North America has the highest market share in 2021 and is expected to maintain its lead during the forecast period, owing to higher adoption of advanced prenatal and newborn genetic testing devices, rise in pregnancy rate, and availability of well-developed healthcare infrastructure. However, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to improvement in health awareness, development in healthcare facilities, adoption of prenatal and newborn genetic testing, and a surge in healthcare expenditure.  

  Key findings of the study  

• On the basis of product type, the consumables segment dominated the market in 2021.  

• On the basis of screening, non-invasive prenatal testing (NIPT) segment dominated the market in 2021.  

• On the basis of disease, Down syndrome segment dominated the market in 2021.  

• On the basis of end user, hospital segment dominated the market in 2021.  

• On the basis of region, North America dominated the market in 2021 and is expected to grow at a CAGR of 10.7%